SLAM BioTherapeutics
Preclinical-stage biotechnology company developing antibody-based therapeutics for hematologic malignancies. The company advances antibody-drug conjugates (ADCs) and bispecific antibody programs that target a SLAM-family cell-surface receptor (SLAMF5 / CD84) with the intent to enter first-in-human studies in 2026. Activities include antibody discovery and engineering, preclinical in vitro and in vivo assessment, IND-enabling work, and academic partnerships to support translational development.
Industries
N/A
Nr. of Employees
small (1-50)
SLAM BioTherapeutics
3148 Versaille Court, Thousand Oaks, California 91362, United States
Products
Lead antibody-drug conjugate targeting SLAMF5 (CD84)
A preclinical lead ADC program that targets a SLAM-family receptor (SLAMF5/CD84) overexpressed in several hematologic malignancies; reported to be scheduled for clinical entry in 2026.
Bispecific T-cell engager programs targeting SLAM-family receptors
Preclinical bispecific antibody programs designed to engage T cells and target tumor cells expressing SLAM-family receptors.
Lead antibody-drug conjugate targeting SLAMF5 (CD84)
A preclinical lead ADC program that targets a SLAM-family receptor (SLAMF5/CD84) overexpressed in several hematologic malignancies; reported to be scheduled for clinical entry in 2026.
Bispecific T-cell engager programs targeting SLAM-family receptors
Preclinical bispecific antibody programs designed to engage T cells and target tumor cells expressing SLAM-family receptors.
Services
Collaborative research with academic institutions and foundations to advance preclinical antibody programs toward clinical testing.
Collaborative research with academic institutions and foundations to advance preclinical antibody programs toward clinical testing.
Expertise Areas
- Antibody therapeutics
- Antibody-drug conjugate (ADC) development
- Bispecific antibody and T-cell engager development
- Immuno-oncology and tumor microenvironment modulation
Key Technologies
- Antibody-drug conjugates (ADCs)
- Bispecific antibody engineering
- Antibody humanization and affinity optimization
- CRISPR/Cas9 gene editing
News & Updates
Announcement of appointment of Chan Whiting, PhD, as Chief Scientific Officer and commentary on her experience in translational science and R&D strategy.
Strategic investment and collaboration with a foundation to accelerate development of therapies for follicular lymphoma and other blood cancers.
Seed funding round reported (over $8M) to support preclinical development and IND-enabling studies for lead assets.
Seed round reported at over $8 million to support preclinical development and IND-enabling studies.
Reported raising more than $10 million in seed funding and plans to initiate a $30+ million Series A round to support Phase 1a/1b trials and pipeline expansion.
Announcement of appointment of Chan Whiting, PhD, as Chief Scientific Officer and commentary on her experience in translational science and R&D strategy.
Strategic investment and collaboration with a foundation to accelerate development of therapies for follicular lymphoma and other blood cancers.
Seed funding round reported (over $8M) to support preclinical development and IND-enabling studies for lead assets.
Seed round reported at over $8 million to support preclinical development and IND-enabling studies.
Reported raising more than $10 million in seed funding and plans to initiate a $30+ million Series A round to support Phase 1a/1b trials and pipeline expansion.